nocturnal

Iptacopan hydrochloride (LNP023 hydrochloride) 是一种可口服、高效和高选择性的因子 B 抑制剂，IC50 为 10 nM。 LNP023 显示与人因子 B 的直接、可逆和高亲和力结合，KD 为 7.9 nM。

Famotidine (MK-208) 是一种具有抗酸活性的丙脒和组胺 H2 受体拮抗剂。

1,2-Dimethoxybenzene是由Silene latifolia分泌天然产物，是对夜行性蛾Hadena bicruris有效传粉的引诱剂。

Desmopressin acetate (16679-58-6 free base) (DDAVP) 是抗利尿激素精氨酸加压素的合成类似物。

AGN-201904Z is a slowly absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) rapidly converted to omeprazole in the systemic circulation giving a prolonged residence time. AGN 201904-Z produced a significantly greater, and nocturnal acid suppression

Desmopressin (DDAVP) 是抗利尿激素精氨酸加压素的合成类似物。

Lupitidine hydrochloride inhibits nocturnal acid secretion.

Cisapride tartrate is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be e......

Ravulizumab (ALXN1210) 是一种靶向补体因子 5 的人源化单克隆抗体，它以高亲和力特异性结合人补体蛋白 C5，可阻断补体激活。Ravulizumab 可用于预防和治疗阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征和重症肌无力。

Crovalimab (SKY59; RO7112689)是一种人源化抗C5抗体，其通过pH依赖性机制发挥作用，其KD值在pH 7.4时为15.2nM，在pH 5.8时为16.8μM。该化合物还以高亲和力结合于人FcRn(KD: 17μM; pH 6.0)。通过阻断C5转化酶对C5的切割及抑制C5变体(p.Arg885His)的活性，Crovalimab能够显著抑制补体系统中经典途径(CP)、凝集素途径(LP)以及旁路途径(AP)中C5b-9的形成。因此，Crovalimab展现出作为研究阵发性睡眠性血红蛋白尿(PNH)及其他补体介导疾病的潜力。

Danicopan (ACH-4471) 是一种可口服的小分子 D 因子选择性抑制剂，对人 D 因子具有高结合亲和力，Kd 值为 0.54 nM。 它可抑制补体替代途径 (APC) 的活性，具有阻断阵发性夜间血红蛋白尿 (PNH) 和非典型溶血性尿毒症综合征 (aHUS) 的补体替代途径的潜力。

(Z)-10-Hexadecen-1-ol 是由部分夜蛾雌性或大黄蜂 (Bombus spp.) 雄性头部分泌的一种昆虫性信息素。